|Bid||6,450.00 x 6100|
|Ask||6,451.00 x 13000|
|Day's Range||6,388.00 - 6,477.00|
|52 Week Range||5,110.00 - 6,545.00|
|Beta (3Y Monthly)||1.11|
|PE Ratio (TTM)||33.91|
|Earnings Date||Jul 25, 2019|
|Forward Dividend & Yield||2.15 (3.34%)|
|1y Target Est||78.83|
Andrew Lindsay, chief executive of Telecom Plus, calls the 12-month period to March 2019 “a turnaround year” from five years of “slowly reducing growth rates”. Customer numbers rose by 4 per cent to 635,039, and the group supplied 2.5m services to its club members — up by 8.2 per cent.
On March 28, AstraZeneca (AZN) issued a press release announcing its collaboration with Daiichi Sankyo for the development and commercialization of trastuzumab deruxtecan, an investigational therapy currently being evaluated for multiple HER2-expressing cancers.
In the first quarter, Lynparza garnered revenue of $237 million for AstraZeneca (AZN), a YoY (year-over-year) rise of more than 105% driven mainly by its ongoing launch as a second-line maintenance therapy for ovarian cancer and as a therapy for germline BRCA-mutated metastatic breast cancer in the US and Japan.
Lynparza, being jointly developed by AstraZeneca along with U.S. drugmaker Merck & Co , can now be used in patients who are in response following chemotherapy for advanced BRCA-mutated ovarian cancer in Europe, AstraZeneca said. BRCA genes are responsible for producing proteins which repair damaged DNA, and if the genes are mutated, they can cause cancer growth.
British drugmaker AstraZeneca Plc on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel's consent in April. Lynparza, being jointly developed by AstraZeneca along with U.S. drugmaker Merck & Co, can now be used in patients who are in response following chemotherapy for advanced BRCA-mutated ovarian cancer in Europe, AstraZeneca said.
AstraZeneca's (AZN) Tagrisso was approved by the FDA first for the treatment of epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer and then as a first-line therapy for EGFR-mutated NSCLC. The drug has become the highest-selling drug in AstraZeneca’s portfolio.
On its first-quarter earnings conference call, AstraZeneca (AZN) guided for year-over-year product sales growth in high-single-digit percentage in 2019. The company, however, expects modest product sales growth in the second half of 2019 due to higher oncology revenue in the previous period.
Merck & Co. (MRK) is up 8.49%, and AstraZeneca (AZN) is up 5.08% in 2019 on a year-to-date basis. Merck continues to ride on the success of its leading immuno-oncology drug, Keytruda. AstraZeneca’s oncology drugs Tagrisso and Lynparza have emerged as key revenue drivers for it in 2019.
An encouraging 88% of patients on CALQUENCE remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine
At Insider Monkey we follow nearly 750 of the best-performing investors and even though many of them lost money in the last couple of months of 2018 (some actually delivered very strong returns), the history teaches us that over the long-run they still manage to beat the market, which is why it can be profitable […]
In Phase IIIb DIALIZE trial, 41.2% of LOKELMA patients maintained normal potassium levels pre-dialysis compared to 1% receiving placebo
FARXIGA showed a 47% reduction in the composite of kidney function decline, end-stage renal disease or renal death in a pre-specified analysis from DECLARE-TIMI 58
A look at the shareholders of AstraZeneca PLC (LON:AZN) can tell us which group is most powerful. Institutions will...
British drugmaker AstraZeneca Plc is preparing to search for a successor to Chairman Leif Johansson, Sky News reported https://bit.ly/2Zals8B on Monday. AstraZeneca's board is in the early stages of planning for an eventual replacement for Johansson, who has chaired the company for seven years, according to the report. There was no scheduled timetable in place yet for Johansson's departure, Sky News reported, citing sources.
The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines Private equity firms circle Bayer's animal medicine unit ...
AstraZeneca and Merck & Co's Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go nearly twice as long without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial presented on Sunday. BRCA mutations are typically linked with breast and ovarian cancers, but occur in other cancers as well. Lynparza was tested against a placebo as a maintenance therapy in 154 patients with metastatic pancreatic cancer whose tumors had not progressed after chemotherapy.
Data presented at ASCO 2019 showed 57% of patients alive at three years vs. 43.5% on placebo
Inovio Pharmaceuticals Inc. shares fell in the extended session Tuesday after the drug developer said that one of its partners is scaling back on a research collaboration. Inovio shares fell 6.7% after hours, following a 3.7% decline to close at $3.14. In a filing with the Securities and Exchange Commission, Inovio said AstraZeneca PLC subsidiary MedImmune is discontinuing a research agreement with the company with the exception of a drug candidate known as "MEDI0457." The companies will continue evaluating the drug for use in cancers associated with human papillomavirus, or HPV, and Inovio will be eligible for milestone payments should the drug receive market approval.
It's the local company's first step toward establishing an international presence after it was spun out last year from MedImmune.
The extended weekend is now over, and Wall Street is once again paying attention to the U.S. China trade war, the Indian stock market now that Modi has been reelected as well as various economic indicators. Among the stocks trending this weekend are Alibaba Group Holding Limited (NYSE:BABA), General Motors Company (NYSE:GM), Tesla Inc. (NASDAQ:TSLA), MGM Resorts International (NYSE:MGM), […]
AstraZeneca, in continued partnership with Bob Harper, a health and fitness expert, best-selling author and heart attack survivor, today announced the expansion of the Survivors Have Heart movement, taking its mission across the United States to unite heart attack survivors nationwide and elevate the importance of daily heart health management. The tour will kick off with a stop in Tampa, Florida, on June 5th, connecting local survivors with Bob Harper to share stories of strength and resilience. Further, the Survivors Have Heart initiative will bring together cardiovascular patient advocacy organizations, healthcare providers, policymakers and other community leaders to celebrate survivorship and champion the importance of cardiovascular health as part of a long-term healthy lifestyle.